Elsevier Acquires Oncology Journal Portfolio From Cancer Information Group

NEW YORK, February 2, 2011 /PRNewswire-FirstCall/ --

- Journals Provide the Highest Quality Content Focused on Tumor-Specific Topics That Affect Oncologists and Their Patients

Elsevier (http://www.elsevier.com), the leading global publisher of scientific, technical, and medical information products and services, announced today that it acquired the oncology portfolio of journals previously published by CIG Media Group LP., (operated as Cancer Information Group). The journals publish peer-reviewed, disease specific original research and review articles that disseminate cutting-edge data to physicians, medical researchers and health care professionals.

"These journals provide an excellent addition to Elsevier's oncology portfolio and will further enhance the depth and quality of oncology content published by Elsevier," said Glen P. Campbell, Executive Vice President, Global Medical Research, for Elsevier. "We look forward to working with the editorial teams and to leveraging Elsevier's global resources and market-leading online platforms for the continued development and growth of the quality, international profile and visibility of these prestigious journals."

The specific journal titles are: Clinical Breast Cancer, Clinical Lung Cancer, Clinical Lymphoma Myeloma & Leukemia, Clinical Colorectal Cancer, Clinical Ovarian Cancer, and Clinical Genitourinary Cancer.

"Authors will benefit from the upcoming release of enhanced online manuscript submission and review systems for the journals, as well as the range of author support tools provided by Elsevier," said Campbell.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com/) and Cell ( http://www.cell.com/), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect (http://www.sciencedirect.com/), SciVerse Scopus (http://www.scopus.com/home.url), Reaxys (https://www.reaxys.com/info/), MD Consult (http://www.mdconsult.com/php/234517366-4423/homepage) and Nursing Consult (http://www.nursingconsult.com/php/234713837-2/home.html), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com/) and MEDai's Pinpoint Review ( http://www.medai.com/), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier ( http://www.elsevier.com/wps/find/homepage.cws_home) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC ( http://www.reedelsevier.com/Pages/Home.aspx), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

    Media Contact

    Tom Reller
    VP, Corporate Relations, Elsevier
    [email protected]
    +1-215-239-3508

SOURCE Elsevier

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.